RT Journal Article
SR Electronic
T1 The Path Forward to Biomarker Discovery in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 434
OP 436
DO 10.3899/jrheum.111243
VO 39
IS 2
A1 DAFNA D. GLADMAN
A1 CHRISTOPHER T. RITCHLIN
A1 OLIVER FITZGERALD
YR 2012
UL http://www.jrheum.org/content/39/2/434.abstract
AB At the 2010 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), wide-ranging discussions were held regarding biomarker research in psoriatic disease. Consensus was reached on 2 areas of priority: (1) the study of soluble biomarkers of radiographic progression in psoriatic arthritis (PsA); and (2) the analysis of comorbidity biomarkers, specifically cardiovascular and articular, in a psoriasis inception cohort. For each of these areas, rigorous definition of the clinical phenotype of PsA will be essential. To date, 2 instruments have been identified to define the phenotype: the ClASsification of Psoriatic ARthritis criteria and various screening questionnaires. In this overview, we discuss the challenges of the clinical phenotype of PsA and review GRAPPA plans for developing a research program for biomarker discovery.